CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

What happened: CRISPR Therapeutics reported a third-quarter 2026 loss of $1.15 per share, wider than the Zacks Consensus Estimate of a loss of $1.06, while total revenues of $12.7 million beat the $9.9 million estimate. Key numbers: Loss per share $1.15 vs. estimate $1.06; year-ago loss $1.17. Revenue $12.7 million vs. Why it matters: Casgevy sales momentum and the $2.28 billion cash position support the pipeline, and the stock carries a Zacks Rank #3 (Hold). Multiple clinical updates are expected before year-end, including phase Ib CTX310 data on Nov. 9, 2026. Market: -0.1% today ($20.21), +59.6% YTD, 0.2x vol — as of 17:48 UTC

CRISPR Therapeutics reported a third-quarter 2026 loss of $1.15 per share, wider than the Zacks Consensus Estimate of a loss of $1.06, while total revenues of $12.7 million beat the $9.9 million estimate.

Casgevy sales momentum and the $2.28 billion cash position support the pipeline, and the stock carries a Zacks Rank #3 (Hold). Multiple clinical updates are expected before year-end, including phase Ib CTX310 data on Nov. 9, 2026. Market: -0.1% today ($20.21), +59.6% YTD, 0.2x vol — as of 17:48 UTC